title: A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.
abstract: BACKGROUND
  Teduglutide, a recombinant analog of human glucagon-like peptide (GLP)-2, is a novel therapy recently approved for the treatment of adult patients with short bowel syndrome who are dependent on parenteral support. Previous studies assessing the effect of GLP-2 on gastric emptying in humans have yielded inconsistent results, with some studies showing no effect and others documenting a GLP-2-dependent delay in gastric emptying. The primary objective of this study was to assess the effect of teduglutide on gastric emptying of liquids in healthy subjects, as measured by the pharmacokinetics of acetaminophen.
  
  
  METHODS
  This double-blind, parallel-group, single-center study enrolled and randomized 36 healthy subjects (22 men, 14 women) to receive subcutaneous doses of teduglutide 4 mg or placebo (2:1 ratio; 23:13) once daily on Days 1 through 10 in the morning. Gastric emptying of a mixed nutrient liquid meal was assessed by measuring acetaminophen levels predose and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 3.5, 4, 5, 6, 8, 10, 12, and 14 hours after administration of 1000 mg acetaminophen on Days 0 and 10. The primary study endpoint was a pharmacokinetic analysis of acetaminophen absorption in subjects receiving teduglutide or placebo.
  
  
  RESULTS
  No significant differences in gastric emptying of liquids (acetaminophen area under the concentration [AUC] vs time curve from time 0 to the last measurable concentration, AUC extrapolated to infinity, maximum concentration [Cmax], and time to Cmax) were observed on Day 10 in subjects receiving teduglutide 4 mg versus subjects receiving placebo. There were no serious adverse events (AEs), deaths, or discontinuations due to an AE reported during the study.
  
  
  CONCLUSIONS
  Teduglutide 4 mg/day for 10 days does not affect gastric emptying of liquids in healthy subjects as measured by acetaminophen pharmacokinetics. No unexpected safety signals were observed.
  
  
  BACKGROUND
  This study was registered at ClinicalTrials.gov, identifier NCT01209351.
authors: DaVita Clinical Research, 825 S, 8th Street, Suite 300, Minneapolis, MN 55404, USA. jolene.berg@davita.com.
authors: Jolene Kay
authors: JK
authors: Berg
authors: Eric H
authors: EH
authors: Kim
authors: Benjamin
authors: B
authors: Li
authors: Bo
authors: B
authors: Joelsson
authors: Nader N
authors: NN
authors: Youssef
mesh_terms: D000042:Absorption / Q000187:drug effects; D000082:Acetaminophen / Q000493:pharmacokinetics*; D000328:Adult; D019540:Area Under Curve; D004311:Double-Blind Method; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D005765:Gastrointestinal Agents; D010455:Peptides; D000082:Acetaminophen; C494910:teduglutide